

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached Schedule A.

I hereby appoint:

☒ Practitioners associated with the Customer Number: 75093

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 75093

OR

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email


Assignee Name and Address:

Salix Pharmaceuticals, Inc.  
1700 Perimeter Park Drive  
Morrisville, North Carolina 27560

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

### SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	9/2/10
Name	Carolyn J. Logan	Telephone	919-862-1000
Title	President and CEO		

## Schedule A

App. No.	Filing Date	Inventor	Atty. Dkt. No.	Title
11/592,854	11/03/06	Johnson	119557-01901	FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES
11/835,897	08/08/07	Johnson	119557-01902	FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES
11/877,589	10/23/07	Johnson	119557-01903	FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES
12/628,072	11/30/09	Johnson	119557-01904	FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES
10/988,693	11/16/04	Skiendzielewski et al.	119557-00802	COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
12/075,772	03/13/08	Skiendzielewski et al.	119557-00803	COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
10/588,254	08/14/08	Bettenhausen et al.	119557-00402	PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS
08/829,080	03/31/97	Jacob et al.	119557-01001	NON-AQUEOUS COLONIC PURGATIVE FORMULATIONS
08/669,377	07/11/96	Johnson et al.	119557-00202	USE OF 2-HYDROXY-5-PENYLAZOBENZOIC ACID DERIVATIVES AS COLON CANCER CHEMOPREVENTATIVE AND CHEMOTHERAPEUTIC AGENTS
08/178,578	01/07/1994	Johnson et al.	119557-00201	USE OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES AS COLON CANCER CHEMOPREVENTATIVE AND CHEMOTHERAPEUTIC AGENTS